ADXS


Stock Update (NASDAQ:ADXS): Advaxis, Inc. Secures a $30M Direct Placement Financing to Healthcare Specialist Investors

Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that it has entered into a definitive securities purchase agreement with healthcare …

Company Update (NASDAQ:ADXS): Advaxis, Inc. Advances AXAL Into Second Stage of Phase 2 Clinical Study

Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that its Phase 2 “window of opportunity” clinical study of its lead …

H.C. Wainwright Weighs in on Advaxis, Inc (ADXS) Following Commercial Deal with Amgen (AMGN)

Analyst Swayampakula Ramakanth of H.C.

Stock Update (NASDAQ:ADXS): Advaxis, Inc. and Amgen Enter Global Cancer Immunotherapies Collaboration

Advaxis, Inc. (NASDAQ:ADXS) and Amgen (NASDAQ:AMGN) announced a global agreement for the development and commercialization of Advaxis’ ADXS-NEO, a novel, preclinical investigational cancer immunotherapy …

Stock Update (NASDAQ:ADXS): Advaxis, Inc. Announces Completion of Second Dose-Escalation Cohort for Phase 1/2 Combination Trial of AXAL and Durvalumab

Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced its combination study of axalimogene filolisbac (AXAL) with AstraZeneca’s anti-PD-L1 durvalumab …

Stock Update (NASDAQ:ADXS): Advaxis, Inc.’s AXAL Receives Fast Track Designation by the FDA as Adjuvant Therapy for High-Risk Locally Advanced Cervical Cancer Patients

Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that the U.

Company Update (NASDAQ:ADXS): European Medicines Agency Committee Classifies Advaxis, Inc.’s Axalimogene Filolisbac as an Advanced-Therapy Medicinal Product

Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that its lead Lm immunotherapy candidate, axalimogene filolisbac (AXAL), has been …

Company Update (NASDAQ:ADXS): Advaxis, Inc. Appoints Ranya Dajani as Vice President, Corporate Development

Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced Ranya Dajani joined Advaxis as Vice President, Corporate Development from Bristol-Myers …

FBR Reiterates Outperform on Advaxis, Inc. (ADXS) Following SPA Agreement With FDA

In a research report published on Thursday, FBR analyst Vernon Bernardino reiterated an Outperform rating on shares of Advaxis, Inc. (NASDAQ:ADXS) with a price …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts